ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, today announced a second service and license agre...
Original Article: ProBioGen and Pionyr Immunotherapeutics initiate second collaboration